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a carbonyl iron supplemented on hepatic and pancreatic tissues,
oxidative stress markers and liver peroxisome proliferator activated
receptor α expressions. Hamsters were divided: Control which
received a standard AIN 93 diet; Control Iron, composed of control
animals that received a diet with 0.83% carbonyl iron; Diabetic,
composed of animals that received a injection of streptozotocin
(50 mg/kg, intraperitoneal) on day 35; and Diabetic Iron composed
of streptozotocin treated animals that received a diet supple 
mented with carbonyl iron. Diabetes increased the glucose level
and reduced triglycerides. Diabetic Iron group showed higher levels
of glucose and serum triglycerides as compared to the Diabetic
group. Diabetes decreased mRNA levels of peroxisome proliferator 
activated receptor α. Iron attenuated the diabetes induced down
regulation of peroxisome proliferator activated receptor α mRNA.
Moreover, diabetes increased carbonyl protein and decreased
glutathione levels and catalase activity, while iron attenuated the
increase in levels of carbonyl protein and attenuated the decrease
in those of glutathione level and catalase activity. Histological
analysis shows that supplementation iron caused an increase in
the size of the islets in Control Iron. The results show that iron
does not aggravated liver oxidant/antioxidant status and per 
oxisome proliferator activated receptor α expression in diabetic
hamsters.
Key Words: carbonyl iron, streptozotocin, oxidative stress, 
hamsters, PPAR α
Introduction Diabetic mellitus, a chronic metabolic disorder, is one of the
most important health problems in the world, especially in
developing countries. It is characterized by imperfection in insulin
secretion and insulin receptor or post receptor events with
derangement in carbohydrate, protein and lipid metabolism and
results in chronic hyperglycemia.(1) Chronic hyperglycemia, pro-
motes glucotoxicity, and has negative impacts on various organs
and tissues, such as pancreas, liver, kidneys, muscles, etc. Gluco-
toxicity eventually leads to progressive β-cell dysfunction, im-
paired insulin gene transcription and permanent β-cell loss due to
apoptosis, ensuing in a vicious cycle with exasperation of the
hyperglycemia.(2) Indeed, hyperglycemia is contemplated to gen-
erate reactive oxygen species through diverse pathways, such as
mutilation of the redox equilibrium, augmentation of advanced
glycation products, activation of protein kinase C or overproduc-
tion of mitochondrial superoxides that eventually leading to oxida-
tive stress in a variety of tissues.(3) The vulnerability of each tissue
to oxidative stress can vary depending upon their expressed
antioxidant enzymes. In addition to the pancreatic β-cells, supra-
physiological glucose is notorious to provoke oxidative stress in
hepatocytes which can cause hepatic tissue damages.(4,5)
Dietary components can modify the redox status of an organism
and appear as an important factor in controlling diabetes and its
complications. Nutrients such as iron have a dual role, with the
ability to increase or decrease the organism’s redox capacity. Iron,
acting as a cofactor for many proteins, including antioxidant
enzymes, is essential for cellular metabolism and aerobic respira-
tion. However, in high concentrations it can lead to cellular
toxicity and oxidative damage of cellular components due to its
role in the formation of free radicals.(6,7)
Association between excessive systemic iron and diabetes was
suggested by the observation that the incidence of diabetes is
increased in classical hereditary hemochromatosis,(8) in which
there is a large increase in iron pools. Epidemiological data show
a positive correlation between body iron pools and development of
glucose intolerance seen in both diabetes type 2(9–11) and gestational
diabetes.(12) Recently, have been demonstrated, in a mouse model
of hereditary hemochromatosis, that glucose uptake is increase in
skeletal muscle but glucose oxidation is decreased and the ratio of
fatty acid to glucose oxidation is increased, that may to contribute
to the risk of diabetes with excessive tissue iron.(13)
Together, these observations suggest that there is a close rela-
tionship between iron and diabetes pathophysiology. However,
not much data exist regarding this relationship in experimental
models. Such models would allow better understanding of the
mechanisms involved in this interaction and could contribute to a
better control of diabetes and to a reduction of its complications
when associated to iron supplementation.
To expand knowledge in between diabetes and iron, we sought
to describe the effect of iron and diabetes on oxidative stress,
liver histology, and lipid homeostase by studying the effects on
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peroxisome proliferator-activated receptor-α (PPAR-α) mRNA in
liver of hamsters with a diet supplemented with carbonyl iron, an
iron for oral use. A growing body of evidence supports the role of
PPAR-α in the development of liver disease and as a putative
target for the treatment of steatohepatitis. Disabling the PPAR-α
gene is known to increase hepatic triglyceride accumulation,
especially under conditions of fasting.(14–16) Pharmacological
PPAR-α activation has been shown to lower hepatic triglyceride
levels and effectively attenuate steatohepatitis.(17–19) Furthermore,
diabetes can modulate PPARs through increased inflammatory
cytokines and oxidative stress in the heart.(20) Thus it is possible
to suppose that the interaction between iron and diabetes might
modulate the PPAR-α expression in the liver and, as a conse-
quence, the lipid homeostasis.
We also studied histologic caracteristics of pancreas sections.
This study allowed us to analyze possible iron effects without
excessive iron overload by using the hamster as a model, because
this animal has a lipoprotein profile similar to that of humans. This
allowed us to establish parallels between the alterations seen here
and those known to occur in humans, making this a useful model
to unravel the mechanisms involved in this relationship. This
relationship is especially relevant in developing countries, which
have an increasing incidence of diabetes as well as iron deficiency
anemia(21) and, therefore, where an indiscriminate iron supple-
mentation occurs.
Materials and Methods
Animals and experimental design. Female Golden Syrian
hamsters, weighing approximately 100 g, were obtained from the
School of Nutrition of the Federal University of Ouro Preto and
kept in collective cages in rooms with controlled temperature and
humidity and with 12-h light and dark cycles. Hamsters received
food and water ad libitum. Experiments were conducted according
to the principles defined by the Brazilian College of Animal
Experimentation.(22) Animal procedures were approved by the Ethics
Committee of the Federal University of Ouro Preto. Hamsters
were divided into four groups of eight animals each were normal-
ized by weight. The control (C) group received the standard
AIN-93 diet.(23) Control Iron group (CI) received the standard
diet supplemented with 0.83% carbonyl iron according to Dabbagh
et al.(24) Diabetic group (D) received an injection of streptozotocin
(STZ) at 50 mg/kg, intraperitoneal, according to Iancu et al.,(25) on
experimental day 35 and was kept on the standard diet. Diabetic
Iron (DI) received the STZ injection and was kept on the standard
diet supplemented with 0.83% carbonyl iron. Seven days after the
STZ injection, glucose levels were measured, and only animals
with glucose levels above 250 mg/dl remained in the experimental
group. The total experimental time was 45 days.
Sample preparation. On experimental day 45, fasting ham-
sters were anesthetized and euthanized by an intraperitoneal
injection of pentobarbital (Sigma, 60 mg/kg body weight). Blood
samples were collected and centrifuged in 1.5 ml tubes for
determination of serum components. Liver and pancreas were
removed, weighed and stored either in liquid nitrogen or buffered
formaldehyde for biochemical and histopathological analysis,
respectively.
Assay methods. The concentration of serum iron was deter-
mined by spectrophotometric analysis using Labtest kit # 38
(Minas Gerais, Brazil) with a standard iron solution (500 μg/dl).
Liver samples, 100 mg, were digested in 2 ml of nitric acid at
100°C. Excess acid was evaporated and iron levels were quantified
by colorimetric analysis according to the Association of Official
Analytical Chemistry (AOAC),(26) using the orthophenanthroline
assay with an iron solution of 500 μg/dl as an external iron
standard. Labtest kits # 53, 42, 99 and 19 were used to measure the
activities of serum alanine aminotransferase (ALT), aspartate
aminotransferase (AST), serum concentration of total proteins and
albumin, respectively. Glucose and fructosamine concentrations
and amylase activity were determined using Labtest kits # 84, 97
and 25 respectively. Triglycerides and total cholesterol concentra-
tions were measured using Labtest kits # 59 and 60 with glycerol
or cholesterol as standards, respectively. Following low density
lipoprotein (LDL) and very low density lipoprotein (VLDL)
precipitation with phosphotungstic acid and MgCl2, high density
lipoprotein (HDL) cholesterol was measured in the supernatant
using Labtest kit # 3. The remaining cholesterol fractions were
calculated based on the difference between total and HDL
cholesterol.
Histopathological evaluation. Liver and pancreas frag-
ments not exceeding 4 mm in diameter were fixed in 10% formal-
dehyde solution and then dehydrated, diaphanized and embedded
in paraffin. Paraffin sections of approximately 4 μm were obtained
by sectioning embedded fragments on a rotary microtome. Sections
were mounted on glass slides previously cleaned and degreased.
Slides were stained with Hematoxylin and Eosin for visualization
of histological changes and with Perls’ technique for determina-
tion of tissue iron pools. Digital morphometric analysis, conducted
for determination of the average size and area of pancreatic islets
as well as quantification of tissue iron pools, were done using a
Leica DM5000 optical microscope with the Leica analysis soft-
ware Qwin Plus.
Quantitative real time RT PCR assay. Trizol RNA extrac-
tion of liver, approximately 50 mg, was done using RNAgents®
Promega-Total RNA Isolation System (Madison) according to
the manufacturer’s recommendations. Total RNA concentration
and purity was determined by spectrophotometric analysis at 260
and 280 nm on a NanoVue spectrophotometer (GE Healthcare,
United Kingdom). cDNA was synthesized from total RNA using
GeneAmp® RNA PCR (Applied Biosystems, Foster City). Briefly,
cDNA was prepared in a 20 μl reaction using MultiScribeTM
(50 U/μl) Reverse Transcriptase and Oligo d(T)16 primers (Applied
Biosystems). Gene expression was analyzed using SYBR Green
PCR Master Mix (Applied Biosystems). PPAR-α gene expression
was normalized to that of β-actin. Primer sequences were as
follows: F-TGTCGAATATGTGGGGACAA and R-AAACGG-
ATTGCATTGTGTGA for PPAR-α and F-ACTGGCATTGTG-
ATGGACTC and R-GTGGTGGTGAAGCTGTAGCC for β-
actin. cDNA was amplified at 95–60°C for 40 cycles in an ABI
7300 Real-Time PCR instrument (Applied Biosystems). All
samples were analyzed in triplicate. Measurement of relative
PPAR distribution was done for each animal. Cycle Threshold
values (ΔCT) were obtained by subtracting β-actin CT values
from the respective PPAR CT values.
Activity of enzyme and antioxidant compound. Total
glutathione concentration (GSH and GSSH) in liver homogenates
was determined using Sigma Kit CS0260 (EUA). This assay utilizes
a kinetic method to measure glutathione based on the reduction of
DTNB (5,5'-dithio-bis-(2-nitrobenzoic) acid) to TNB, which can
be spectrophotometrically determined at 412 nm. Sigma G4251
reduced glutathione was used as a standard.
Catalase activity was determined according to Aebi.(27) Briefly,
10 μl of tissue homogenate supernatant were added to a cuvette
containing 2 ml of 50 mmol/l phosphate buffer (pH 7.2). The
reaction was initiated by the addition of 1 ml of substrate (30 mM
H2O2 in phosphate buffer). The rate of H2O2 decomposition was
measured spectrophotometrically in 1-min intervals at 240 nm
against a blank containing phosphate buffer instead of substrate.
The decomposition of hydrogen peroxide was calculated using the
molar extinction coefficient 39.41 l.mol−1/cm−1. One U of catalase
is equivalent to the hydrolysis of 1 μmol of H2O2 per minute.
Protein oxidation analysis. Carbonyl protein was measured
by using the modified method of Levine.(28) In brief, 0.5 ml of
supernatant was placed in two tubes. Then 0.5 ml of 10 mM 2,4-
dinitrophenylhydrazine (DNPH) in 2.5 M HCl was added to one
of the tubes, while 0.5 ml of HCl (2.5 mM) was added to the other.doi: 10.3164/jcbn.10 135
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Tubes were then left for 30 min at room temperature. Samples
were vortex-mixed every 15 min. Then 0.5 ml of trichloroacetic
acid (TCA) (20%, wt/vol) was added, and the tubes were left on
ice for 5 min followed by centrifugation for 10 min at 5.000 g, to
collect the protein precipitates. The pellets were then washed two
times with 1 ml of ethanol/ethyl acetate (1:1, vol/vol). The final
precipitates were dissolved in 1 ml of SDS 6%, followed by
centrifugation for 10 min, at 10.000 g. Absorbance of the sample
was measured at 370 nm. The carbonyl content was calculated based
on the molar extinction coefficient of DNPH (22000 mol−1/cm−1)
and expressed as nmol/mg of protein. The content of total liver
protein was determined according to Lowry et al.(29)
Statistical analysis. Data were analyzed by the Kolmogorov–
Smirnov test. All data, except for the expression of PPAR-α, were
found to follow a normal distribution and were analyzed by the
bivariate analysis of variance (two-way ANOVA). Classification
factors were diabetes and iron, as well as their interaction.
Whenever an effect was found for one of the factors, we used the
univariate variance test (one-way ANOVA) with Tukey post test to
determine the differences between groups. The data for PPAR-α
expression were analyzed by Kruskal Wallis test. Results were
expressed as mean ± standard deviation.
Results
Iron status, biochemical indicators of hepatic function
and body and liver weights. The concentration of iron in the
serum was twice as high in animals from the CI group as compared
to animals in the C group (Table 1). This result is in contrast to
animals in group DI, whose serum iron concentrations were
comparable to those of animals in group C. Surprisingly, animals
of group D had higher concentrations of serum iron than those in
group C. Iron levels in the liver were also analyzed, and, in this
case, we found that animals whose diet was supplemented with
carbonyl iron, namely groups CI and DI, had iron levels equivalent
to 6- and 4.4-fold those of group C, respectively. We found that
hamsters with STZ-induced diabetes presented reduced body
weight as compared to the control group. This weight loss was
more pronounced in the DI group (Table 1). Liver weight was also
decreased in diabetic animals. To determine whether iron excess
and/or diabetes caused hepatic injury, ALT and AST activities
and albumin and total protein concentrations were measured. ALT
activity was higher in hamsters in group D as compared to those in
group C. However AST activity was higher in animals receiving
iron supplementation, i.e., groups DI and CI. The concentration
of total proteins in serum was lower in both groups of diabetic
hamsters, namely D and DI. The concentration of albumin did not
vary with any of the analyzed variables, remaining similar in all
groups.
Glycemic and lipid profile. To determine the effects of iron
on glucose and lipid homeostasis, the glycemic and lipid profiles
of all groups were analyzed (Table 1). As expected, animals that
received STZ injections had increased glucose and fructosamine
levels. Glucose levels in animals of group D were 2.6 times higher
than those in group C, whereas fructosamine levels were 1.8 times
higher in group D than in group C. Amylase activity, on the other
hand, was decreased by 5.1% in group D as compared to group C.
The administration of excess iron potentiated the changes in the
glycemic profile caused by diabetes. Animals of group DI had
glucose levels 3.56 times higher than those in group C. Amylase
activity was further decreased by 5% in group DI. The concentra-
tion of serum triglycerides was higher in group DI than in groups
D and CI, with no significant difference noted between these and
group C. Hamsters of group DI showed decreased total serum
cholesterol as compared to the other groups. Data analysis of HDL
cholesterol concentration showed that this was also decreased in
animals of groups DI and D. The later showed an increase in the
other cholesterol fractions that was not seen in group DI.
Histological analysis. Histological analysis showed that,
overall, the liver of animals in group C was normal. There were
some ballooned hepatocytes that had large and clear cytoplasm
(Fig. 1A), indicating the presence of a hydropic degenerative
Table 1. Iron status, biochemical indicators of hepatic function, body and liver weights, glycemic and lipids profile of hamsters
ALT, alanine aminotransferase; ANOVA, analysis of variance; AST, aspartate aminotransferase; HDL, high density lipoprotein; ¶ Values are shown as
the mean ± standard deviation (n = 8). Data were analyzed by bivariate ANOVA analysis. When one of the factors was significant (p<0.05) univariate
analysis with Tukey post test was performed to determine specific differences between means. Statistical differences are shown by different super 
script letters.
Variables
Experimental groups
Control Control + Iron Diabetes Diabetes + Iron
ANOVA (p values)
Iron Diabetes Iron × Diabetes
Laboratory Data
Serum Iron μmol/l 36.45 ± 5.34c 73.34 ± 9.89a 52.71 ± 5.57b 40.06 ± 7.68c <0.00001 0.001 <0.00001
Liver Iron μmol 0.69 ± 0.24c 4.38 ± 0.22a 0.83 ± 0.11c 3.09 ± 0.65b <0.00001 0.417 <0.0001
ALT U/ml 44.55 ± 10.26b 61.16 ± 13.87b 115.12 ± 58.39a 70.75 ± 21.65a.b 0.219 0.004 0.019
AST U/ml 47.66 ± 5.2b 55.37 ± 12.87a.b 49.29 ± 6.53b 64.68 ± 13.33a 0.0037 0.153 0.241
Albumin μmol/l 302.2 ± 43.66 315.18 ± 18.39 298.09 ± 9.65 292.07 ± 18.17 0.674 0.172 0.336
Total Protein g/l 30.13 ± 3.13a 31.33 ± 2.31a 26.32 ± 2.09b 25.51 ± 1.1b 0.761 <0.00001 0.248
Glucose mmol/l 7.07 ± 1.15c 7.15 ± 0.99c 18.44 ± 4.94b 25.15 ± 1.96a 0.0003 <0.00001 0.007
Fructosamine μmol/l 9.35 ± 1.71c 11.72 ± 2b.c 16.86 ± 1.9a 14.34 ± 2.6a.b 0.618 <0.00001 0.003
Amylase U/dl 770.59 ± 5.67a 735.95 ± 21.3b 731.09 ± 7.37b 726.47 ± 5.37b 0.0001 <0.0001 0.001
Cholesterol mmol/l 3.03 ± 0.44a 3.49 ± 0.59a 2.89 ± 0.4a 1.91 ± 0.33b 0.192 <0.00001 0.0001
Triglycerides mmol/l 2.49 ± 0.49a.b 1.94 ± 0.62b 2.28 ± 0.35b 3.39 ± 0.93a 0.356 0.0049 0.001
HDL mmol/l 1.57 ± 0.22a 1.84 ± 0.38a 0.93 ± 0.11b 0.88 ± 0.11b 0.293 <0.00001 0.05
Other Fractions mmol/l 1.46 ± 0.3b.c 1.64 ± 0.58a.b 2.04 ± 0.36a 1.03 ± 0.31c 0.02 0.555 0.0004
Anthropometric Data
Final Body Weight g 130.88 ± 12.99a.b 136.11 ± 14.25a 113.55 ± 17.92b.c 105.13 ± 14.08c 0.893 <0.0001 0.177
Autopsy Data
Liver Weight g 4.36 ± 0.36a 4.91 ± 0.69a 3.61 ± 0.62b 3.49 ± 0.43b 0.0938 <0.00001 0.221 J. Clin. Biochem. Nutr. | September 2011 | vol. 49 | no. 2 | 105
©2011 JCBN
M. Silva et al.
process. These are generally associated with inflammatory pro-
cesses with a predominance of mononuclear cells, mainly macro-
phages. This inflammatory process occurred in the presence of
normal levels of iron stores. Animals of the CI group showed a
moderate presence of ballooned hepatic cells, which were diffuse
throughout the parenchymal tissue. This presentation is generally
associated with granulomatous inflammatory foci, and tissue iron
stores were located primarily in hepatocytes and Kupfer cells
(Fig. 1 C and E).
The most important lesion found in animals of groups D and DI
was the presence of numerous hepatic cells with multiple intra-
cytoplasmic vesicles presenting as a negative image on HE
staining, which is a morphologic indication of multilocus
steatosis. In animals of group D, steatosis was mild, located in
hepatic portal regions (Fig. 1B) and was associated with the
presence of small inflammatory foci without the presence of
tissue iron stores. In animals of the DI group, the steatosis was also
mild, but in this case, it was diffused throughout all areas of the
liver and was associated with small inflammatory foci and tissue
iron pools (Fig. 1 D and F). Histological analysis of Perls for C
and D groups showed no iron deposits.
Pancreatic analysis showed that animals in group CI had
pancreatic islets one fold higher than animals in group C. However,
animals in both groups D and DI showed average size of pancreatic
islets equal as compared to those in group C (Fig. 2). Total
percentage of the pancreatic area occupied by islets was 8.23%
for group C and 10.24% for group CI, both of which were signifi-
cantly higher than those observed for groups D and DI, in which
the percentage was 2.98% and 4.82%, respectively (Fig. 2).
Histological studies showed no changes in cell profiles in any of
the pancreatic regions. Furthermore, no tissue iron pools in all
groups analyzed was seen.
Antioxidant status. Results of these analyses are shown in
Table 2. We found that diabetes reduced the antioxidant status in
the liver, as it caused a decrease of 8.5% and 33% in hepatic
glutathione and catalase activities, respectively. However, an
interaction of excess iron with diabetes, led to an increase in this
antioxidant status as seen by the activities of both glutathione and
catalase in the liver.
Liver carbonyl protein. As shown in Table 2, levels of
carbonyl protein in the liver of animals from group D were found
to be 41% higher than those in group C. Animals in group DI had
carbonyl protein levels equal to those in group C.
PPAR α/β actin relative levels in the liver. Fig. 3 shows
qPCR analysis of the expression of PPAR-α in the liver of diabetic
hamsters and in the liver of those whose diets were supplemented
with excess iron. PPAR-α mRNA levels were significantly lower
(85%) in group D as compared to group C. However, excess iron
did not alter the expression of PPAR-α mRNA.
Discussion
Iron treatment increased serum and tissue iron levels. Surpris-
ingly, although both control and diabetics groups have received
the same treatment with carbonyl iron, apparently, animals that
received both treatments presented an alteration in iron home-
ostasis, leading to a lower concentration of iron in serum and
liver. It is known that the amount of plasma iron is determined
by a regulated liberation of iron from most cells of the body.
Macrophages, intestinal enterocytes, and hepatocytes have a
particularly important role in this process, and this cellular efflux
is modulated by liver hepcidin.(30) Fernandez Real et al.(31) verified
that hepcidin levels increased significantly in patients with type 2
diabetes. Our data suggest that the interaction between iron
supplementation and diabetes triggers changes in iron home-
ostasis, contributing to a lower absorption, resulting in lower iron
levels in serum and liver. This effect can also be attributed to
insulin since in vitro data suggest that it is capable of redistributing
the cellular pool of transferring receptors, increasing the propor-
tion at the cell surface, leading to increased cellular iron uptake in
adipose tissue and the liver.(32) In our experimental model STZ
destroys the beta cells, promoting insulin deficiency, which may
have caused a smaller deposit of iron in the DI group as compared
to CI. Our data on glycemic and lipids profile, besides the histo-
logical aspect of the pancreas showed a detrimental interaction
between diabetes and iron. These data support those from epide-
miological studies which show a correlation between increased
iron pools and diabetes. On the other hand, the histological aspect
of the liver in group DI followed the same profile of D group and
the liver antioxidant levels were increased as compared to group
D. Our results show the different tissue vulnerability to ferro-
diabetes interaction. Damage through reactive oxygen species is
determined not only by the generation of free oxygen radicals
but also by the antioxidant defense status of the cell. This is why
different organs can exhibit considerable differences in their
susceptibility towards cytotoxic damage. Lenzen et al.(33) showed
that in pancreatic islets very low levels of gene expression of all
antioxidant enzymes are observe compared to liver. Further, seem
that the higher expression of PPAR-α and lower oxidative stress
played an important role in hepatic integrity. The histological data
obtained here indicate that our model of iron supplementation
caused less damage to the liver, as we did not see any fibrosis,
Fig. 1. Photomicrographs of histological liver sections. (A) Control
group showing normal histology with a small number of cells under 
going a degenerative process (arrow). (B) Diabetic group featuring
some hepatic cells with microvesicular cytoplasm indicative of the
steatosis process (arrowheads). (C) Control group receiving the diet
supplemented with iron (group CI) featuring ballooned hepatic cells
(stars) suggesting a hydropic degenerative process and focal granulo 
matous inflammation (arrow). (D) Diabetic group receiving a diet
supplemented with iron showing histology similar to B. Arrowhead
indicates cells with cytoplasmic microvesicles. (E) Control group receiving
a diet supplemented with iron and (F) diabetic group receiving a diet
supplemented with iron and featuring iron deposits in hepatocytes.
Insert showing citoplasmatic iron store in hepatocyte (head arrow) and
Kupffer cell (star) in ×1110 magnification A, B, C and D—Hematoxylin &
Eosin staining. E and F—Perls staining. Bar = 50 μM.doi: 10.3164/jcbn.10 135
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thereby suggesting preservation of the metabolic functions, what
was further supported by total protein and albumin concentrations.
When we consider the activity of ALT, a marker of liver function,
the DI group showed intermediate levels between C and D. This
corroborates with data of oxidative stress and PPAR-α expression
in the liver, indicating that the interaction of iron with diabetes
reversed damage caused by the disease. As for AST activity, it was
shown to be increased in the animals that received iron supple-
mentation, whether they were diabetic or not. An increase in the
concentration of AST may reflect damage to other organs such as
muscle, since it is not distributed in various tissues. The data of
activity of these enzymes also allow us to suppose that the inter-
action between iron and diabetes promoted different effects on
the different tissues, possibly because the susceptibility of these
tissues to oxidative stress is different.
In the present study we have found differential expression of
liver PPAR-α among diabetic and iron-induced diabetic hamsters.
PPAR-α was expressed at relatively lower levels in the diabetic
animals. Previous studies have shown that the expression of
PPAR-α can be regulated by diabetes. Marcill et al.(34) showed
that oxidative stress decreases PPAR-α expression in macrophages
of diabetics animals. Furthermore, Wang et al.(35) investigated the
expression of PPAR-α in aorta, renal cortex and retina of diabetic
rats and found it to be decreased in all studied tissues, besides Li
et al.(36) having shown that type 2 diabetic hamsters also had
decreased expression of this mRNA in the liver. It has been pre-
viously indicated that oxidative stress increases during dia-
betes(37,38) and contributes to down-regulation of PPAR-α in atrial
myocytes both in vitro(39) and in vivo.(20) In the present study,
diabetes significantly increased oxidative stress as evaluated by
increasing carbonyl protein and decreasing glutathione levels
and catalase activity, but was attenuated in iron-treated diabetic
hamsters. The effectiveness of iron-diabetes to attenuate oxidative
stress might be due to the greater induction of NF-E2-related
factor 2 (Nrf2) target genes. This activation induces the production
of antioxidant compounds and enzymes.(40,41) Tanaka et al.(42) have
demonstrated that coordinated induction of Nrf2 target genes
protects against iron nitrilotriacetate (FeNTA)-induced nephro-
Fig. 2. Photomicrographs of histological pancreatic sections. (A) Control group. (B) Diabetic group. Note the decrease of the size of pancreatic
islets as compared to the control group. (C) Control group receiving the iron supplemented diet and showing significant increase of pancreatic islets
as compared to all other groups. (D) Diabetic group receiving iron supplemented diet. Note the decreased size of pancreatic islet as compared to the
control group. Hematoxylin & Eosin staining. Bar = 50 μM. Figure E  Average size of pancreatic islets from hamsters fed standard diet (C), diet
supplemented with carbonyl iron (CI), diabetes (D) and diabetes supplemented with carbonyl iron (DI)*.
* Values are mean ± standard deviation (n = 6). Data were analyzed by bivariate ANOVA analysis. When one of the factors was significant (p<0.05),
univariate analysis with Tukey post test was performed to determine specific differences between means. Statistical differences are shown by
different superscript letters.
Table 2. Hamster antioxidant and carbonyl protein levels
¶ Values are shown as the mean ± standard deviation (n = 8). Data were analyzed by bivariate ANOVA analysis. When one of the factors was
significant (p<0.05) univariate analysis with Tukey post test was performed to determine specific differences between means. Statistical differences
are shown by different superscript letters.
Variables
Experimental Groups
Control Control + Iron Diabetes Diabetes + Iron
ANOVA (p values)
Iron Diabetes Iron × Diabetes
Liver glutathione 
nmoles/ml 40.43 ± 4.81a 40.12 ± 1.61a 34.77 ± 3.06b 40.01 ± 5.47a 0.146 0.0383 0.097
Liver catalase μmol/mg 
protein 18.30 ± 3.19a 16.75 ± 3.274a 12.16 ± 1.34b 17.67 ± 2.36a 0.104 0.01 0.002
Liver carbonyl protein 
nmol/mg protein 2.25 ± 1.2b 3.24 ± 1a.b 3.74 ± 0.76a 3.18 ± 0.63a.b 0.685 0.108 0.0445 J. Clin. Biochem. Nutr. | September 2011 | vol. 49 | no. 2 | 107
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toxicity. Our results concerning antioxidants suggest that the inter-
action between diabetes and iron alters the redox balance and
accounts for increased antioxidant levels, thus contributing to a
higher expression of PPAR-α mRNA.
Reduced expressions of PPAR-α have been associated with
lipid accumulation.(43) Increased concentration of triglycerides
and reduced HDL levels are key characteristics of dyslipidemia in
diabetes.(44) Previous studies have shown that excess iron can
increase the concentration of triglycerides in the circulation.(45)
Although increases in LDL-cholesterol and triglycerides are
common in diabetic dyslipidemia, we did not observe changes in
the levels of these metabolites in our diabetes model, probably
due to the fact that in STZ-induced diabetes there is a reduction in
insulin secretion.(46) When iron was associated with diabetes,
lower cholesterol and higher triglyceride levels were observed.
Our data suggest that the alterations in serum lipid homeostasis in
group DI are independent of PPAR-α expression because the
levels of expression of this mRNA were comparable to the group
C and higher than the D groups; this was possibly due to the strong
influence of insulin deficiency. HMG-CoA reductase, a key
enzyme in the synthesis of cholesterol, has its activity stimulated
by this hormone, thus lower insulin levels would lead to less
cholesterol synthesis, justifying our data for cholesterol. Lower
activity of lipoprotein lipase can contribute to higher levels of
triglycerides because this enzyme is essential to the removal of
triglycerides from the blood stream and further degradation and
it is attenuated in insulin deprivation. Furthermore, although there
is no significant difference between body weight of animals in
groups D and DI, there is a tendency of group DI to have lower
body weight than group D. When we analyzed glucose levels of
these two groups it was observed that they were higher in the DI
group, suggesting a reduced production of insulin, which can lead
to increased lipolysis and proteolysis in this group, leading to
greater weight loss in the DI animals as compared to the DI group.
Our data support those from epidemiological studies which
show a correlation between increased iron pools and diabetes. It
has been reported in clinical studies that increased iron levels in
serum and specific tissues may increase the incidence of type 2
diabetes(32,47) and gestational diabetes.(48) Iron depletion has been
demonstrated to be beneﬁcial in coronary artery responses, endo-
thelial dysfunction, insulin secretion, insulin action, and metabolic
control in type 2 diabetes.(49) Our results show that iron supple-
mented in diabetes type I model increased serum concentrations
of glucose. The interaction between iron and diabetes promoted
different effects on the liver and pancreas, possibly because the
susceptibility of these tissues to oxidative stress is different.
Besides, for the ﬁrst time, we have shown that PPAR-α expression
is differentially expressed in diabetic and iron supplemented-
diabetic hamsters livers.
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